Trial Profile
A Phase II, Single Arm, Open Label Study of Treatment-Free Remission in Chronic Myeloid Leukemia (CML) chronic phase (CP) patients After Achieving Sustained MR4.5 on Nilotinib
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 04 Mar 2024
Price :
$35
*
At a glance
- Drugs Nilotinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
- Acronyms ENESTop
- Sponsors Novartis; Novartis Pharma A.G.; Novartis Pharmaceuticals; Novartis Pharmaceuticals Corporation
- 27 Feb 2024 Planned End Date changed from 6 Feb 2025 to 31 Jan 2025.
- 26 Mar 2022 This trial has been completed in Greece, according to European Clinical Trials Database record.
- 08 Dec 2020 Results assessing long term TFR outcomes at more than 5 years and of post hoc analysis evaluating rates of regain of molecular response following NIL reinitiation in patients with loss of major molecular response or confirmed loss of MR4.0 at a follow up of 5 years presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology